Condensed Consolidated Statements of Equity (Unaudited) - USD ($) shares in Millions, $ in Millions	Total	Common stock	Treasury Stock, Common	Additional paid-in capital	Retained earnings	Accumulated other comprehensive loss	Noncontrolling interest
Beginning balance at Dec. 31, 2021	$ 15,436	$ 18	$ (3,143)	$ 18,305	$ 3,127	$ (2,899)	$ 28
Beginning balance (in shares) at Dec. 31, 2021		1,768
Increase (Decrease) in Stockholders' Equity
Net earnings attributable to AbbVie Inc.	9,363	$ 0	0	0	9,363	0	0
Other comprehensive income (loss), net of tax	(544)	0	0	0	0	(544)	0
Dividends declared	(7,537)	0	0	0	(7,537)	0	0
Purchases of treasury stock	(1,483)	$ 0	(1,483)	0	0	0	0
Purchases of treasury stock (in shares)		(10)
Stock-based compensation plans and other	787	$ 0	36	751	0	0	0
Stock-based compensation plans and other (in shares)		10
Change in noncontrolling interest	5	$ 0	0	0	0	0	5
Ending balance at Sep. 30, 2022	16,027	$ 18	(4,590)	19,056	4,953	(3,443)	33
Ending balance (in shares) at Sep. 30, 2022		1,768
Beginning balance at Jun. 30, 2022	14,688	$ 18	(4,591)	18,906	3,516	(3,196)	35
Beginning balance (in shares) at Jun. 30, 2022		1,768
Increase (Decrease) in Stockholders' Equity
Net earnings attributable to AbbVie Inc.	3,949	$ 0	0	0	3,949	0	0
Other comprehensive income (loss), net of tax	(247)	0	0	0	0	(247)	0
Dividends declared	(2,512)	0	0	0	(2,512)	0	0
Purchases of treasury stock	(4)	$ 0	(4)	0	0	0	0
Purchases of treasury stock (in shares)		0
Stock-based compensation plans and other	155	$ 0	5	150	0	0	0
Stock-based compensation plans and other (in shares)		0
Change in noncontrolling interest	(2)	$ 0	0	0	0	0	(2)
Ending balance at Sep. 30, 2022	16,027	$ 18	(4,590)	19,056	4,953	(3,443)	33
Ending balance (in shares) at Sep. 30, 2022		1,768
Beginning balance at Dec. 31, 2022	17,287	$ 18	(4,594)	19,245	4,784	(2,199)	33
Beginning balance (in shares) at Dec. 31, 2022		1,769
Increase (Decrease) in Stockholders' Equity
Net earnings attributable to AbbVie Inc.	4,041	$ 0	0	0	4,041	0	0
Other comprehensive income (loss), net of tax	(154)	0	0	0	0	(154)	0
Dividends declared	(7,892)	0	0	0	(7,892)	0	0
Purchases of treasury stock	(1,969)	$ 0	(1,969)	0	0	0	0
Purchases of treasury stock (in shares)		(12)
Stock-based compensation plans and other	814	$ 0	38	776	0	0	0
Stock-based compensation plans and other (in shares)		8
Change in noncontrolling interest	2	$ 0	0	0	0	0	2
Ending balance at Sep. 30, 2023	12,129	$ 18	(6,525)	20,021	933	(2,353)	35
Ending balance (in shares) at Sep. 30, 2023		1,765
Beginning balance at Jun. 30, 2023	12,898	$ 18	(6,528)	19,839	1,789	(2,252)	32
Beginning balance (in shares) at Jun. 30, 2023		1,765
Increase (Decrease) in Stockholders' Equity
Net earnings attributable to AbbVie Inc.	1,778	$ 0	0	0	1,778	0	0
Other comprehensive income (loss), net of tax	(101)	0	0	0	0	(101)	0
Dividends declared	(2,634)	0	0	0	(2,634)	0	0
Purchases of treasury stock	(4)	$ 0	(4)	0	0	0	0
Purchases of treasury stock (in shares)		0
Stock-based compensation plans and other	189	$ 0	7	182	0	0	0
Stock-based compensation plans and other (in shares)		0
Change in noncontrolling interest	3	$ 0	0	0	0	0	3
Ending balance at Sep. 30, 2023	$ 12,129	$ 18	$ (6,525)	$ 20,021	$ 933	$ (2,353)	$ 35
Ending balance (in shares) at Sep. 30, 2023		1,765